Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th
Bright Minds Biosciences announced the initiation of Phase 2 clinical trial of BMB-101 in a group of drug-resistant epilepsies and will discuss the details of the BREAKTHROUGH clinical trial on September 25th The event will feature Epilepsy KOLs to discuss the unmet needsfor epilepsy treatment. BMB-101 is the first 5-HT2C agonist in clinical studies designed…
